Cryptococcosis Associated With Biologic Therapy: A Narrative Review

Resource type
Journal Article
Authors/contributors
Title
Cryptococcosis Associated With Biologic Therapy: A Narrative Review
Abstract
Abstract Cryptococcus is an opportunistic fungal pathogen that can cause disseminated infection with predominant central nervous system involvement in patients with compromised immunity. Biologics are increasingly used in the treatment of neoplasms and autoimmune/inflammatory conditions and the prevention of transplant rejection, which may affect human defense mechanisms against cryptococcosis. In this review, we comprehensively investigate the association between cryptococcosis and various biologics, highlighting their risks of infection, clinical manifestations, and clinical outcomes. Clinicians should remain vigilant for the risk of cryptococcosis in patients receiving biologics that affect the Th1/macrophage activation pathways, such as tumor necrosis factor α antagonists, Bruton tyrosine kinase inhibitors, fingolimod, JAK/STAT inhibitors (Janus kinase/signal transducer and activator of transcription), and monoclonal antibody against CD52. Other risk factors—such as age, underlying condition, and concurrent immunosuppressants, especially corticosteroids—should also be taken into account during risk stratification.
Publication
Open Forum Infectious Diseases
Volume
11
Issue
7
Pages
ofae316
Date
2024-06-28
Language
en
ISSN
2328-8957
Short Title
Cryptococcosis Associated With Biologic Therapy
Accessed
7/9/24, 7:55 PM
Library Catalog
DOI.org (Crossref)
Citation
Li, X., Paccoud, O., Chan, K.-H., Yuen, K.-Y., Manchon, R., Lanternier, F., Slavin, M. A., Van De Veerdonk, F. L., Bicanic, T., & Lortholary, O. (2024). Cryptococcosis Associated With Biologic Therapy: A Narrative Review. Open Forum Infectious Diseases, 11(7), ofae316. https://doi.org/10.1093/ofid/ofae316
Link to this record